BVS - Bioventus Inc.
Preborsa:
| Chiusura precedente | 2,7000 |
| Aperto | 2,7300 |
| Denaro | 0,8200 x 1800 |
| Lettera | 3,0300 x 1800 |
| Min-Max giorno | 2,5900 - 2,9250 |
| Intervallo di 52 settimane | 0,8000 - 9,8950 |
| Volume | |
| Media Volume | 768.415 |
| Capitalizzazione | 181,211M |
| Beta (5 anni mensile) | 0,29 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -4,0400 |
| Prossima data utili | 09 ago 2023 - 14 ago 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 2,50 |
GlobeNewswireBioventus Completes Divestiture of its Wound Business
DURHAM, N.C., May 23, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has successfully completed the divestiture of its Wound business, including the skin substitutes TheraSkin and TheraGenesis, to LifeNet Health. The transaction, announced earlier this month, enables Bioventus’ improved focus on execution and delivers approximately $30 million of net closing proceeds, which will be u
- GlobeNewswire
Bioventus Reports First Quarter Financial Results
DURHAM, N.C., May 16, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three months ended April 1, 2023. Q1 Financial Summary: Net Sales of $119.1 million, up $1.8 million, or 1.5%, year-over-year as reported (1.9% constant currency*)Net Loss from continuing operations of $100.0 million, compared to Net Loss from continuing operations of $14.4 million in prior-year per
- GlobeNewswire
Bioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023
DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will now report financial results for the first quarter of fiscal year 2023 after the market closes on Tuesday, May 16, 2023. The Company’s management will host a conference call at 5:00 p.m. Eastern Time that same day to discuss the results and provide a business update. At this time, the Company expects to report
- GlobeNewswire
Bioventus Reschedules Earnings Call to May 16, 2023; Files for Extension to File Form 10-Q for the Period Ended April 1, 2023
DURHAM, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today the Company plans to file Form 12b-25, Notification of Late Filing, for its Quarterly Report on Form 10-Q for the period ended April 1, 2023, on May 11, 2023. Due to complexity of its tax structure and the associated impact on the calculation of noncontrolling equity interest in the equity section of the Company’s balance s
- GlobeNewswire
Bioventus Announces Divestiture of its Wound Business
DURHAM, N.C., May 10, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has signed a definitive agreement to sell its Wound business, including the skin substitutes TheraSkin and TheraGenesis, to LifeNet Health. The transaction includes a total cash consideration of $85 million, including $35 million in cash at close, a $5 million cash payment deferred 18 months, and $45 million in pote
- GlobeNewswire
Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023
DURHAM, N.C., May 03, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2023 before the market opens on Thursday, May 11, 2023. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-8
- GlobeNewswire
Bioventus Announces CEO Leadership Change
DURHAM, N.C., April 05, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced that Ken M. Reali has stepped down as Chief Executive Officer (CEO) and as a member of the Board of Directors (board). The board has initiated a comprehensive search process to identify a permanent CEO. Until a successor is named, the board has appointed Anthony Bihl, as interim CEO, effective immediately. Bihl is a seasoned ex
- GlobeNewswire
Bioventus Reports Fourth Quarter and Full-Year 2022 Financial Results
DURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the year ended December 31, 2022. Q4 Financial Summary & Recent Highlights: Net Sales of $125.8 million, down $4.6 million, or (3.5%), year-over-year as reported ((2.9%) constant currency* and down (9.5%) organically* (9.0%) constant currency*)Net Loss of $44.9 million, compared to Net Loss of $1.9 mi
- GlobeNewswire
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
DURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has entered into an Amendment No. 4 (the “Amendment”) to the Credit and Guaranty Agreement, between the Company, Wells Fargo Bank, National Association as Administrative Agent and Collateral Agent, and the Lenders from time to time party thereto, dated as of December 6, 2019 and as amended on August 29, 2021, Octo
- GlobeNewswire
Bioventus Reschedules Reporting of Fourth Quarter Fiscal Year 2022 Financial Results to March 31, 2023
DURHAM, N.C., March 29, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will now report financial results for the fourth quarter of fiscal year 2022 before the market opens on Friday, March 31, 2023, rather than as previously announced to allow additional time to complete its financial statements. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same
- GlobeNewswire
Bioventus to Report Fourth Quarter of Fiscal Year 2022 Financial Results on March 30, 2023
DURHAM, N.C., March 16, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2022 before the market opens on Thursday, March 30, 2023. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dia
- GlobeNewswire
Bioventus Enters into Settlement Agreement to Preserve Maximum Optionality – Up To $350mm of Potential Liability Reduction and a Release of Future Claims related to the CartiHeal Acquisition
DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has entered into a Settlement Agreement (the “Settlement Agreement”) with the former CartiHeal shareholders (the “CartiHeal Sellers”) regarding the Company’s obligations under the amended Option and Equity Purchase Agreement for its prior acquisition of CartiHeal (the “Amended Acquisition Agreement”). The Settlemen
- GlobeNewswire
Bioventus to Present at the 41st Annual J.P. Morgan Healthcare Conference
DURHAM, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Ken Reali, chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 5:15 p.m. PT (8:15 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available until February 10, 2023. About BioventusBio
- GlobeNewswire
Bioventus Issues Revised Third Quarter Results; Updates Full-Year 2022 Financial Guidance
DURHAM, N.C., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today amended its previously announced financial results for the three and nine months ended October 1, 2022. Due to the adverse effect on the previously announced third quarter 2022 financial results and revenue guidance that resulted from additional rebate claims related to certain of the Company’s products and a non-cash impairment cha
- GlobeNewswire
Bioventus Files for Extension to File Form 10-Q for the Period Ended October 1, 2022
DURHAM, N.C., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today the Company has filed a Form 12b-25, Notification of Late Filing for its Quarterly Report on Form 10-Q for the period ended October 1, 2022. As a result of the recent decline in the Company’s market capitalization subsequent to its previously announced financial results for the third quarter of 2022 ("Q3 Earnings Release")
- GlobeNewswire
Bioventus Reports Third Quarter Results; Updates Full-Year 2022 Financial Guidance
DURHAM, N.C., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended October 1, 2022. Q3 Financial Summary & Recent Highlights: Net Sales of $137.1 million, up $28.2 million, or 25.9%, year-over-year as reported (26.8% constant currency*) and 7.3% organically* (8.1% constant currency*)Net Income of $3.2 million, compared to Net Loss of $2
- GlobeNewswire
Bioventus to Report Third Quarter of Fiscal Year 2022 Financial Results on November 8, 2022
DURHAM, N.C., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2022 before the market opens on Tuesday, November 8, 2022. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial
- GlobeNewswire
Bioventus to Showcase Full Orthobiologics and Ultrasonic Portfolio at NASS in Chicago
Full Launch of BoneScalpel® Access™ at NASSDURHAM, N.C., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, will present its spine procedural solutions portfolio at the North American Spine Society (NASS) meeting in Chicago, October 12 through 15. By combining the power of the neXus® BoneScalpel® for decompression with OSTEOAMP® bone graft for fusions, Bioventus Procedural Solutions is the go-to portfo
- GlobeNewswire
Bioventus to Present at the Morgan Stanley Global Healthcare Conference
DURHAM, N.C., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice-president and chief financial officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2022, at 11:10 a.m. ET. A live webcast of the fireside chat will be available on the “Investors” section of the Company’s website at www.bioventus.com and will be avail
- GlobeNewswire
Bioventus Reports Second Quarter Results; Updates Full-Year 2022 Financial Guidance
DURHAM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended July 2, 2022. Q2 Financial Summary & Recent Highlights: Net Sales of $140.3 million, up $30.5 million, or 27.8%, year-over-year as reported (28.6% constant currency*) and 8.1% organically* (8.8% constant currency*)Net Loss of ($8.0) million, compared to ($10.8) million in
- GlobeNewswire
Bioventus Receives FDA 510(k) Clearance for SonaStar Elite
Innovative New Handpiece Addition to the Nexus Ultrasonic Generator Significantly Expands Company’s Offering in Neurosurgery Ablation Procedures DURHAM, N.C., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced the US Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s neXus® SonaStar Elite® handpiece. The SonaStar Elite (SSE) handpiece is powered by the neXus Ult
- GlobeNewswire
Bioventus to Report Second Quarter of Fiscal Year 2022 Financial Results on August 11, 2022
DURHAM, N.C., July 26, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2022 before the market opens on Thursday, August 11, 2022. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dia
- GlobeNewswire
Bioventus Completes CartiHeal Acquisition
DURHAM, N.C., July 12, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has completed its acquisition of CartiHeal. “We are excited to add CartiHeal to our diverse portfolio of active healing solutions,” commented Ken Reali, Bioventus’ chief executive officer. “CartiHeal represents an important breakthrough for the treatment of osteoarthritis and osteochondral defects of the knee with
- GlobeNewswire
Bioventus Amends CartiHeal Acquisition Structure
DURHAM, N.C., June 21, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has entered into an amendment to the Option and Equity Purchase Agreement for its pending acquisition of CartiHeal (“Amended Acquisition Agreement”). “CartiHeal represents an important breakthrough for the treatment of osteoarthritis and osteochondral defects of the knee with significant long-term potential, and we